Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-
about
Immunotherapy in Gynecologic Cancers: Are We There Yet?Breast Cancer Immunotherapy: Facts and Hopes.Checkpoint and PARP inhibitors, for whom and when.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Front-line therapy of advanced ovarian cancer: new approaches.Trial watch: Immune checkpoint blockers for cancer therapy.Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.The role of Cediranib in ovarian cancer.miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma.PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Targeting immune checkpoints in breast cancer: an update of early results.Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab.Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.DNA repair defects and implications for immunotherapyPrecision medicine based on tumorigenic signaling pathways for triple-negative breast cancerResponse to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcomaHomologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
P2860
Q38608730-3D3F353E-F5A4-4739-9737-5540B4EC5B28Q38628198-DF5E237A-712E-46D8-A2EE-FFC758B7FD04Q47150508-19A0ED3E-F59C-4147-BA2B-17FE352B7F4EQ47221234-BA4B4980-9980-4650-A2D1-A369A07325B0Q47323988-9B50CE1E-3364-45C6-BC02-9D3327DD15ADQ47393365-9AC4A4F3-4FE8-4053-924B-13047F64D088Q47621538-60141FFD-8604-45DF-82D1-C396CFF39643Q49723005-7909F149-E79C-400C-B5B9-1CB9036892CAQ49966031-4ED6C78D-B06E-49CB-81C6-0550859A8848Q50130129-3DDB20BA-CB41-472E-B061-86F35B73E204Q52585367-E0CD829E-4586-4396-BDCC-BD7CAAC40258Q52715784-8334DC5E-D124-44D3-BC29-F55F4377101AQ54965602-A52E5E81-9314-44A6-BC5E-939BBCBFC34FQ55182988-02E518DF-4B6D-4328-BE6E-CBC1AABF2A19Q55230708-2DE24A8D-BD5D-4302-B252-3506F9BED112Q55665338-6B6CD7F5-8664-49F6-BF5D-648F47F16A2BQ55716958-AAFC4AAE-DA20-4840-A9F6-AC5114DBF183Q57057014-DBD6A255-7FBA-4AF9-95BA-677CB5387C36Q57105411-3F0C781D-F843-4616-865D-964C23CED772Q58766967-300D16B3-1A69-456D-9EDD-210C2FA91A57Q58801181-FDBB9566-A057-450F-9F19-B08E9883606B
P2860
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety and Clinical Activity o ...... ib in Women's Cancers: A Dose-
@en
type
label
Safety and Clinical Activity o ...... ib in Women's Cancers: A Dose-
@en
prefLabel
Safety and Clinical Activity o ...... ib in Women's Cancers: A Dose-
@en
P2093
P2860
P356
P1476
Safety and Clinical Activity o ...... Dose-Escalation, Phase I Study
@en
P2093
Aleksandra Ogurtsova
Alexandra Zimmer
Ashley Cimino-Mathews
Christina M Annunziata
Cody J Peer
Elise C Kohn
Elizabeth M Swisher
Elizabeth Thompson
Haiying Xu
Janis M Taube
P2860
P304
P356
10.1200/JCO.2016.72.1340
P407
P577
2017-05-04T00:00:00Z